Deal of the Day — limited-time pharmacy picks!
Denoci OP 60mg Injection

Denoci OP 60mg Injection

Prescription requiredRx Required

Salt Composition: Denosumab

Expiry Date: 01/2028

Special offer

Buy at $158.82

$158.82

Inclusive of all taxes

▼

1 Prefilled Syringe(s)

About The Product

Bone disease

Description

Denoci OP 60mg Injection is a doctor prescribed injection that used to treat osteoporosis in postmenopausal women and men at high fracture risk, as well as bone loss associated with hormone therapies for breast or prostate cancer, long-term glucocorticoid use, multiple myeloma, and bone metastases.Denoci OP 60mg Injection contains contains 60mg of Denosumab that improves overall bone health.

Indication

Osteoporosis

Dosage And Administration

  • Denoci OP 60mg Injection is administered subcutaneously (under the skin in the lower abdomen), depending on the cancer stage.
  • Patients should not self-administer; it must be injected by a doctor or trained nurse.
  • Consult a doctor for precise dosage and timing.

Mechanism Of Action

Denoci OP 60mg Injection contains 60mg of denosumab( a monoclonal antibody) works by binding to RANK ligand (RANKL), a protein essential for osteoclast formation, function, and survival.Denoci OP 60mg Injection reduces bone resorption, increases bone mineral density, and strengthens bone structure in osteoporosis or cancer-related to bone loss.

Faqs

Denoci OP 60mg Injection is mainly used to treat osteoporosis in postmenopausal women and men at high fracture risk, as well as bone loss associated with hormone therapies for breast or prostate cancer, long-term glucocorticoid use, multiple myeloma, and bone metastases.

References

• Pageau, S. C.

(2009, May). Denosumab.

In MAbs (Vol. 1, No.

3, pp. 210-215).

Taylor & Francis. • Cummings, S. R., Martin, J.

S., McClung, M. R., Siris, E.

S., Eastell, R., Reid, I. R., ... & Christiansen, C.

(2009). Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

New England Journal of Medicine, 361(8), 756-765. • Hanley, D. A., Adachi, J.

D., Bell, A., & Brown, V. (2012).

Denosumab: mechanism of action and clinical outcomes. International journal of clinical practice, 66(12), 1139-1146. • Sheedy, K.

C., Camara, M. I., & Camacho, P.

M. (2015).

Comparison of the efficacy, adverse effects, and cost of zoledronic acid and denosumab in the treatment of osteoporosis. Endocrine Practice, 21(3), 275-279.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026